Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could home monitoring replace half of clinic visits for lung fibrosis?

NCT ID NCT06883448

Knowledge-focused Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether people with pulmonary fibrosis can safely replace half of their regular clinic visits with home monitoring. Participants will use a home spirometer, pulse oximeter, and a smartphone app to track their health and communicate with their care team. The goal is to see if this approach helps patients better manage their own health while reducing the burden of frequent hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
home monitoring care (spirometer, pulse oximeter, app)
What this could lead to
If successful, this could show that home monitoring is a safe and effective way to reduce hospital visits for people with pulmonary fibrosis, improving their quality of life.
What could go wrong
This is an early-stage implementation study with no direct treatment. It may not show clear benefits, and results may not apply to all patients or healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A multidisciplinary ILD team diagnosis of pulmonary fibrosis according to ATS/ERS/JRS/ALAT guidelines; * Adults (=/\>18 years). Exclusion Criteria: * Patients who are not able to speak, read and/or write in Dutch; * Patients with no access to the internet; * Patients with a life expectancy of less than 1 year as determined by the treating healthcare provider; * Patients who are or have been using a home monitoring program for PF.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interstitial lung disease (ILD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung disease (ILD) Pulmonary fibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Pulmonary Diseases, Rijnstate Hospital

    RECRUITING

    Arnhem, Netherlands

  • Department of Pulmonary Medicine, Zuyderland Medical Centre

    RECRUITING

    Heerlen, Netherlands

  • Department of Pulmonology, Haaglanden Medisch Centrum

    RECRUITING

    The Hague, Netherlands

  • Department of Pulmonology, Leiden University Medical Center

    RECRUITING

    Leiden, Netherlands

  • Department of Pulmonology, Medical Center Leeuwarden

    RECRUITING

    Leeuwarden, Netherlands

  • Department of Pulmonology, Onze Lieve Vrouwe Gasthuis

    RECRUITING

    Amsterdam, Netherlands

  • Department of Respiratory Medicine, Amphia Hospital

    RECRUITING

    Breda, Netherlands

  • Department of Respiratory Medicine, Catharina Hospital

    RECRUITING

    Eindhoven, Netherlands

  • Department of Respiratory Medicine, Center of Excellence for Interstitial Lung Disease, Erasmus University Medical Center

    RECRUITING

    Rotterdam, Netherlands

  • Division of Heart and Lungs, University Medical Center Utrecht and Utrecht University

    RECRUITING

    Utrecht, Netherlands

  • Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital

    RECRUITING

    Nieuwegein, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.